PofoliaShared via Pofolia

Pharmaceuticals· 2026Q1· Review

Microneedle-Delivered Plant-Derived Exosome-like Nanovesicles for Dermatological Diseases: A Comprehensive Review

Letong Huang, Hailong Zhang, Jiming Han, Zeng Maoyuan et al.

Short summary

Plant-derived exosome-like nanovesicles (PELNs) combined with microneedles (MNs) show promise for treating skin diseases, but current evidence is fragmented and faces challenges in vesicle identity, preparation consistency, and clinical validation.

AI-generated from the title and abstract; the full text is not read.

Key points

  • Plant-derived exosome-like nanovesicles (PELNs) are being explored as carriers for dermatological treatments.
  • Microneedles (MNs) can enhance the localized delivery of PELNs into the skin.
  • Current research is heterogeneous, including direct PELN-MN studies, PELN-only studies, and mammalian extracellular vesicle analogues.
  • Key limitations include uncertain vesicle identity, co-isolated plant compounds, variable preparation, and insufficient clinical evidence.

AI-generated from the title and abstract; the full text is not read.

Abstract

Plant-derived extracellular vesicle-like nanovesicles (PELNs) are being investigated as plant-derived preparations with intrinsic bioactivity and potential utility as nanocarriers. Microneedles (MNs) can create transient skin microchannels and may support localized intradermal delivery of vesicle-containing formulations. The intersection of these approaches is promising, but the available evidence remains heterogeneous and includes direct PELN–MN studies, PELN studies without MNs, and related mammalian extracellular vesicle platforms. Here we provide a comprehensive review of PELN identity, isolation, characterization, cargo, and proposed dermatological activities, followed by an assessment of MN designs relevant to vesicle delivery. We searched PubMed, Web of Science, Scopus, and Embase, screened records in duplicate, and classified each included study by the directness of evidence into studies providing direct PELN-MN skin evidence, PELN evidence without MNs, mammalian extracellular vesicle MN analogue evidence, and non-dermatological or conceptual evidence. Current limitations include uncertain vesicle identity, co-isolated plant constituents, variable preparation and dosing methods, limited controls for the mechanical effects of microneedling, and incomplete clinical follow-up. Progress toward translation will require source-specific quality attributes, orthogonal potency assays, transparent comparators, and adequately controlled clinical studies.

The authors' abstract, as published at the source. Pharmaceuticals, 2026 · DOI ↗

TakeawaysPremium
Ask the paperFree account

Continue with a free account

Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.

Continue free on the web

Sign in with Google or Apple; no card needed. You come back to this paper.

On your phone:

Field: Pharmaceutical Science

Pharmaceutical SciencePharmacology, Toxicology and Pharmaceutics